Subsidiary of China Meheco Group (600056.SH) obtains approval for registration of Sartansartan Sodium Tablet drug production.

China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical"), has received two "Drug Registration Certificates" issued by the National Medical Products Administration for sodium sacubitril/valsartan tablets. Sodium sacubitril/valsartan is the world's first approved angiotensin receptor neprilysin inhibitor (ARNI) on the market. It is a new type of anti-heart failure medication with better blood pressure lowering effects than standard antihypertensive drugs. It can be used in adult patients with chronic heart failure with reduced ejection fraction (NYHA II-IV, LVEF 40%) to reduce the risk of cardiovascular death and heart failure hospitalization. It can replace angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) when used in combination with other heart failure therapies.